Kangxi Biotech's PCV24 Enters Phase I/II Clinical Trials With First Participant Enrolled

GateNews
Kangxi Biotech's 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) initiated Phase I/II clinical trials with enrollment of the first participant today (May 26), according to a company announcement on the Hong Kong Stock Exchange. The vaccine candidate uses CRM197 and tetanus toxoid as carrier proteins.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments